Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
Eur J Cancer. 2011 Sep;47 Suppl 3:S195-9. doi: 10.1016/S0959-8049(11)70165-4.
The contemporary management of metastatic castration-resistant prostate cancer (mCRPC) is evolving dramatically. Understanding the biology of this disease, positive phase III studies and approvals for 4 novel agents in the US in 2010 and shortly in Europe have dramatically changed the therapeutic landscape.
转移性去势抵抗性前列腺癌（mCRPC）的当代治疗正在发生显著变化。对该疾病生物学特性的理解、3 项阳性 III 期研究以及 2010 年美国和近期欧洲批准的 4 种新型药物，显著改变了治疗格局。
